Short Bowel Syndrome Market Intelligence Report - Global Forecast to 2027

Short Bowel Syndrome Market Intelligence Report - Global Forecast to 2027

The Global Short Bowel Syndrome Market is projected to reach USD 1,625.11 million by 2027 from USD 594.91 million in 2021, at a CAGR 18.23% during the forecast period.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

• The Americas Short Bowel Syndrome Market size was estimated at USD 203.22 million in 2021 and expected to reach USD 237.78 million in 2022, at a CAGR 18.26% to reach USD 555.95 million by 2027.
• The Asia-Pacific Short Bowel Syndrome Market size was estimated at USD 179.53 million in 2021 and expected to reach USD 211.65 million in 2022, at a CAGR 18.55% to reach USD 498.44 million by 2027.
• The Europe, Middle East & Africa Short Bowel Syndrome Market size was estimated at USD 212.15 million in 2021 and expected to reach USD 246.13 million in 2022, at a CAGR 17.93% to reach USD 570.71 million by 2027.

Market Segmentation & Coverage:

The report on short bowel syndrome identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan.

This research report categorizes the short bowel syndrome to forecast the revenues and analyze the trends in each of the following sub-markets:

Drug Class:

• GLP-2
• Glutamine
• Growth Hormone

Distribution Channel:

• Hospital Pharmacies
• Online Sales
• Retail Pharmacies

Region:

• Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
    • California
    • Florida
    • Illinois
    • New York
    • Ohio
    • Pennsylvania
    • Texas
• Asia-Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
• Europe, Middle East & Africa
  • France
  • Germany
  • Italy
  • Netherlands
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • United Arab Emirates
  • United Kingdom

Company Usability Profiles:

• 9 Meters Biopharma, Inc.
• Adocia SAS
• Ardelyx Inc.
• AstraZeneca PLC
• Emmaus Life Sciences, Inc.
• Merck KGaA
• Nestlé S.A.
• Novartis International AG
• OPKO Health, Inc.
• Oxthera AB
• Pfizer Inc.
• PhaseBio Pharmaceuticals Inc.
• Sancilio and Company, Inc.
• Swedish Orphan Biovitrum AB
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• VectivBio AG
• Viatris Inc.
• Zealand Pharma A/S